U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07510815) titled 'Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma' on March 17.
Brief Summary: This example study evaluates locoregional allogeneic dual-target mesothelin/FAP CAR-NK cells in adults with unresectable, recurrent, or refractory pleural or peritoneal mesothelioma.
Eligible participants must have central confirmation of MSLN-positive tumor cells and FAP-positive tumorassociated stroma. The phase 1 portion defines the recommended phase 2 dose and schedule, and the phase 2 expansion explores preliminary antitumor activity, persistence, and biomarker response in pleural and peritoneal disease cohorts.
Study Start ...